Expanded Access Policy

ZyVersa Therapeutics, Inc. is committed to developing first-in-class drugs to improve health outcomes and quality of life for patients with kidney or inflammatory diseases. Our focus is on demonstrating safety and effectiveness of our investigational drugs through clinical trials to achieve regulatory approval and provide broad patient access.

At this stage of our development, we are currently able to offer expanded access (also known as “compassionate use”) on a case-by-case basis only.

As a potential pathway for patients with a serious or life-threatening disease to gain access to investigational therapies when they do not meet clinical trial enrollment criteria nor have available satisfactory treatment options, we understand the importance of the expanded access program. We will continue to evaluate our ability to offer it more broadly in the future.

To determine if you or a patient under your care qualifies for a clinical trial of one of our investigational drugs, please visit clinicaltrials.gov.